Literature DB >> 31739860

Successful Treatment of Somnambulism With OROS-Methylphenidate.

Milan Nigam1,2, Antonio Zadra1,3, Soufiane Boucetta1, Steve A Gibbs1,2,4, Jacques Montplaisir1,5, Alex Desautels1,2,4.   

Abstract

None: Somnambulism is a non-rapid eye movement sleep parasomnia with potential for significant injury as well as functional nighttime and daytime impairment. Clonazepam is frequently used as first line pharmacotherapy. However, the optimal treatment of somnambulism has not been established. In this article, we present the cases of two patients with severe somnambulism who showed a significant therapeutic response to osmotic release oral system methylphenidate (OROS-MPH). In addition to its practical therapeutic implications, this first report of the successful treatment of somnambulism with OROS-MPH may provide additional insight into the neurobiological underpinnings of this medical condition.
© 2019 American Academy of Sleep Medicine.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31739860      PMCID: PMC6853387          DOI: 10.5664/jcsm.8040

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  10 in total

1.  SPECT during sleepwalking.

Authors:  C Bassetti; S Vella; F Donati; P Wielepp; B Weder
Journal:  Lancet       Date:  2000-08-05       Impact factor: 79.321

Review 2.  NREM sleep parasomnias as disorders of sleep-state dissociation.

Authors:  Anna Castelnovo; Régis Lopez; Paola Proserpio; Lino Nobili; Yves Dauvilliers
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

3.  EEG Functional Connectivity Prior to Sleepwalking: Evidence of Interplay Between Sleep and Wakefulness.

Authors:  Marie-Ève Desjardins; Julie Carrier; Jean-Marc Lina; Maxime Fortin; Nadia Gosselin; Jacques Montplaisir; Antonio Zadra
Journal:  Sleep       Date:  2017-04-01       Impact factor: 5.849

Review 4.  Somnambulism: clinical aspects and pathophysiological hypotheses.

Authors:  Antonio Zadra; Alex Desautels; Dominique Petit; Jacques Montplaisir
Journal:  Lancet Neurol       Date:  2013-03       Impact factor: 44.182

5.  Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults.

Authors:  C H Schenck; M W Mahowald
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

6.  Daytime somnolence in adult sleepwalkers.

Authors:  Alex Desautels; Antonio Zadra; Marc-Antoine Labelle; Yves Dauvilliers; Dominique Petit; Jacques Montplaisir
Journal:  Sleep Med       Date:  2013-08-29       Impact factor: 3.492

7.  A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder.

Authors:  F Provini; F Albani; R Vetrugno; L Vignatelli; C Lombardi; G Plazzi; P Montagna
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

8.  Prevalence and genetics of sleepwalking: a population-based twin study.

Authors:  C Hublin; J Kaprio; M Partinen; K Heikkilä; M Koskenvuo
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

Review 9.  Sleep-related epileptic behaviors and non-REM-related parasomnias: Insights from stereo-EEG.

Authors:  Steve A Gibbs; Paola Proserpio; Michele Terzaghi; Andrea Pigorini; Simone Sarasso; Giorgio Lo Russo; Laura Tassi; Lino Nobili
Journal:  Sleep Med Rev       Date:  2015-05-19       Impact factor: 11.609

10.  NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients.

Authors:  Panagis Drakatos; Lucy Marples; Rexford Muza; Sean Higgins; Nadia Gildeh; Raluca Macavei; Eptehal M Dongol; Alexander Nesbitt; Ivana Rosenzweig; Elaine Lyons; Grainne d'Ancona; Joerg Steier; Adrian J Williams; Brian D Kent; Guy Leschziner
Journal:  Sleep Med       Date:  2018-04-10       Impact factor: 3.492

  10 in total
  1 in total

1.  Autonomic Modulation During Baseline and Recovery Sleep in Adult Sleepwalkers.

Authors:  Geneviève Scavone; Andrée-Ann Baril; Jacques Montplaisir; Julie Carrier; Alex Desautels; Antonio Zadra
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.